- Home
- LPTX vs NLSP Comparison
LPTX vs NLSP Comparison
Compare LPTX & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- NLSP
- Stock Information
- Founded
- LPTX 2011
- NLSP 2015
- Country
- LPTX United States
- NLSP Switzerland
- Employees
- LPTX N/A
- NLSP N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- NLSP Health Care
- Exchange
- LPTX Nasdaq
- NLSP Nasdaq
- Market Cap
- LPTX 14.7M
- NLSP 12.4M
- IPO Year
- LPTX N/A
- NLSP 2021
- Fundamental
- Price
- LPTX $0.35
- NLSP $2.24
- Analyst Decision
- LPTX Hold
- NLSP
- Analyst Count
- LPTX 1
- NLSP 0
- Target Price
- LPTX N/A
- NLSP N/A
- AVG Volume (30 Days)
- LPTX 3.3M
- NLSP 308.9K
- Earning Date
- LPTX 08-11-2025
- NLSP 07-29-2025
- Dividend Yield
- LPTX N/A
- NLSP N/A
- EPS Growth
- LPTX N/A
- NLSP N/A
- EPS
- LPTX N/A
- NLSP N/A
- Revenue
- LPTX N/A
- NLSP N/A
- Revenue This Year
- LPTX N/A
- NLSP N/A
- Revenue Next Year
- LPTX N/A
- NLSP N/A
- P/E Ratio
- LPTX N/A
- NLSP N/A
- Revenue Growth
- LPTX N/A
- NLSP N/A
- 52 Week Low
- LPTX $0.22
- NLSP $1.30
- 52 Week High
- LPTX $4.79
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- LPTX 52.39
- NLSP 46.57
- Support Level
- LPTX $0.32
- NLSP $2.06
- Resistance Level
- LPTX $0.36
- NLSP $2.35
- Average True Range (ATR)
- LPTX 0.03
- NLSP 0.22
- MACD
- LPTX 0.01
- NLSP -0.04
- Stochastic Oscillator
- LPTX 86.94
- NLSP 14.33
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.